Kerala Chief Minister
Pinarayi Vijayan on Friday urged the Centre to waive GST and customs duty on a life-saving drug to be imported from the US for the treatment of a child suffering from Spinal Muscular Atrophy (SMA), a rare disease, in the state.
In a letter to Prime Minister Narendra Modi, he detailed the plight of 18-month-old Muhammed, a native of Kannur district, who is undergoing treatment for the disease.
Noting that the medicine for SMA is 'prohibitively expensive' and 'unaffordable' for the child's family, Vijayan said it costs a whopping Rs 18 crore and is proposed to be imported from the US.
The CM, in the letter, also pointed out that the central government had recently waived tax in a similar case of a five month old child, who is suffering from SMA in Mumbai.
"I request you to give directions to the Union Finance Ministry to take steps not to levy Customs duty and integrated Goods and Services Tax (GST) in this case involving the import of the life saving drug zolgensma," he said.
The Chief Minister's plea to the Centre came days after funds for purchasing the drug had been raised in Kerala through online crowdfunding for Muhammed.
Son of P K Rafeeq and Mariyumma, the child requires a dose of Zolgensma, which is considered as one of the most expensive drug in the world.
The treatment committee had on Monday informed the public that over Rs 18 crore reached the bank accounts opened for the donations and asked the people not to deposit any more.
The campaign was taken over by social media resulting in raising the amount within seven days from across the world.
Incidentally, 15-year-old Afra, the elder sister of Mohammed, was also affected with the same disease.
The medicine would have to be procured from abroad and the treatment committee had petitioned the state government to initiate the process for procurement.
Medical experts suggest that the child will have to be administered the dose of the medicine before he reaches the age of two, family sources said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)